electroCore, Inc.
NASDAQ:ECOR

Watchlist Manager
electroCore, Inc. Logo
electroCore, Inc.
NASDAQ:ECOR
Watchlist
Price: 7.38 USD -0.74%
Market Cap: 48.3m USD

electroCore, Inc.
Total Other Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

electroCore, Inc.
Total Other Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Other Income CAGR 3Y CAGR 5Y CAGR 10Y
electroCore, Inc.
NASDAQ:ECOR
Total Other Income
-$389k
CAGR 3-Years
-239%
CAGR 5-Years
-108%
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Total Other Income
-$39m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Boston Scientific Corp
NYSE:BSX
Total Other Income
-$16m
CAGR 3-Years
-21%
CAGR 5-Years
N/A
CAGR 10-Years
-9%
Stryker Corp
NYSE:SYK
Total Other Income
$60m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbott Laboratories
NYSE:ABT
Total Other Income
$558m
CAGR 3-Years
26%
CAGR 5-Years
24%
CAGR 10-Years
N/A
Intuitive Surgical Inc
NASDAQ:ISRG
Total Other Income
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

electroCore, Inc.
Glance View

Market Cap
49.1m USD
Industry
Health Care

electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. The company is headquartered in Rockaway, New Jersey and currently employs 52 full-time employees. The company went IPO on 2018-06-22. nVNS is a platform for bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The firm is providing gammaCore device for the treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults. gammaCore permits patients to self-administer doses of nVNS on an as-needed basis for treatment of prevent multiple types of headache pain via the vagus nerve. The gammaCore therapy is also used to treat primary headache, including migraine, cluster headache (CH), hemicrania continua and paroxysmal hemicrania (PH) and coronavirus (COVID-19).

ECOR Intrinsic Value
20.73 USD
Undervaluation 64%
Intrinsic Value
Price

See Also

What is electroCore, Inc.'s Total Other Income?
Total Other Income
-389k USD

Based on the financial report for Dec 31, 2024, electroCore, Inc.'s Total Other Income amounts to -389k USD.

What is electroCore, Inc.'s Total Other Income growth rate?
Total Other Income CAGR 5Y
-108%

Over the last year, the Total Other Income growth was -111%. The average annual Total Other Income growth rates for electroCore, Inc. have been -239% over the past three years , -108% over the past five years .

Back to Top